“…The HER2 receptor modulates downstream signaling by forming homodimers and heterodimers with other members of the HER family. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The expression of human epidermal growth factor receptor 2 (HER2) protein or gene transcripts is critical for therapeutic decision making in breast cancer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…PURPOSE: We aimed to identify the differently expressed genes or related pathways associated with good responses to anti-HER2 therapy and to suggest a model for predicting drug response in neoadjuvant systemic therapy with trastuzumab in HER2-positive breast cancer patients. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…RESULTS: Compared with the findings from parental DiFi and DiFiG cells, development of acquired resistance to anti-EGFR mAb ICR62 in DiFi62 cells was accompanied by an increase in cell surface EGFR and increased phosphorylation of HER-2 and HER-3. Interestingly, DiFi62 cells also acquired resistance to treatment with anti-EGFR mAbs cetuximab and ICR61, which bind to other distinct epitopes on the extracellular domain of EGFR, but these cells remained equally sensitive as the parental cells to treatment with pan-HER inhibitors such as afatinib. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…TAS0728 is an oral covalent binding inhibitor of human epidermal growth factor receptor 2 (HER2). A first-in-human open-label, dose-escalation, phase I study (NCT03410927) was initiated to investigate the safety and dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) and/or recommended phase II dose of TAS0728 in adults with advanced solid tumors with HER2 or HER3 overexpression, amplification or mutation. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: This study was initiated to investigate the difference in HER2 status between tumor tissue and circulating tumor cells (CTCs), as well as the predictive value of CTC HER2 status for predicting the outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer (MBC) patients. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…PURPOSE: We used targeted capture sequencing to analyze TP53‐mutated circulating tumor DNA (ctDNA) in metastatic breast cancer patients and to determine whether TP53 mutation has predictive value for anti‐human epidermal growth factor receptor 2 (HER2) treatment for in HER2 amplification‐positive patients (HER2+) and HER2 mutation‐positive, amplification‐negative (HER2−/mut) patients. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Childbirth has become increasingly medicalised, which may impact on the mother’s birth experience and her newborn infant’s physiology and behaviour. Although associations have been found between a mother’s subjective birth experience and her baby’s temperament, there is limited qualitative evidence around how and why this may occur. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Nanobodies targeted to human epidermal growth factor receptor 2 (HER2) can be used as tools for the imaging and therapy of HER2-overexpressing tumors. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Currently, different therapeutic regimens are used for BC according to the pathological classification of HER2-positive or HER2-negative. Clinical reports of HER2-low expression indicate that the condition is HER2-negative, which was ineligible for HER2-targeted therapy. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND & OBJECTIVE: Human epidermal growth receptor-2 (HER2) gene amplification is an important predictive and prognostic factor in breast cancer treatment. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: The clinical characteristics and efficacy of human epidermal growth factor receptor‐2 (HER‐2)‐directed agents against HER2 mutations and HER2 fusions in breast cancer are obscure due to their low frequency. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…This review focuses on HER2/neu, a tumour-associated antigen that is overexpressed in 10–40% of breast cancers and other carcinomata. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Of these, the most extensively studied is HER-2(9(369)). In the present report, we used dendritic cells pulsed with HER-2(9(369)) to stimulate, in the presence of IL-7 and IL-12, the production of IFN-γ by patients' CTL detected by the enzyme-linked immunosorbent spot-assay. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: Eighty patients with BM from HER2-positive breast cancer were identified. Karnofsky Performance Score (KPS) of at least 70 was required. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…SRC-1 and SRC-2/TIF-2 mRNA levels were positively correlated with each other and with HER-2 (P ≤ 0.001), and the HER-2 mRNA expression correlated with the levels of the other three HER family members (P < 0.05). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The siRNA and Herceptin mediated downregulation/inhibition of Her-2 in Her-2 amplified cells induced AnxA2 expression and membrane translocation. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: In Asia, large-scale studies on anti-HER2 treatment in HER2-positive breast cancer patients with brain metastases are limited. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We have previously shown that the HER2-specific affibody molecule (Z(HER2∶342))(2) inhibits proliferation of SKBR-3 cells. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In addition, the aptamer was found to preferentially bind to HER2-positive but not HER2-negative breast cancer cells. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso